Rapamycin
The formulation of Rapamycin for the prevention of cancer progression and recurrence.
210 710 2867
info@rapamycinholdings.com
Home
ABOUT US
Management Team
Our Technology
What is eRAPA™?
The Research
Prevention of Cancer Progression and Recurrence
Cognitive Dysfunction
CONTACT US
NEWS
INVESTORS
What is eRapa™?

eRapa™ inhibits the progression and recurrence of cancer. Research has shown Rapamycin rejuvenates the immune system exhausted by age and cancer exposure and helps attack early stage bladder and prostate cancer cells.
The Research

eRapa™ was developed at the Barshop Institute for Longevity and Aging Studies at the University of Texas Health Science Center at San Antonio, and is the only pharmaceutical agent tested thus far to demonstrate significantly increased health span and lifespan in rodent models.
Prevention of Cancer Progression and Recurrence

Early evidence shows a potential for eRapa™ to prevent the progression and recurrence of prostate and bladder cancer, meeting a significant unmet need in the marketplace.
Cognitive Dysfunction

Scientists at the Barshop Institute have demonstrated that orally administered eRapa™ can
prevent the development of Alzheimer’s pathologies in mice.
eRapa™ News

Over the past decade, (Rapamycin) has shown promise as a drug that not only can extend life by delaying the onset of aging-related diseases such as cancer, heart disease, and Alzheimer’s disease, but also postpone the effects of normal aging.
#soliloquy-container-83{opacity:1}
WHAT IS eRAPA™?
eRapa™ inhibits the progression and recurrence of cancer.
Research has shown eRapa rejuvenates the immune system exhausted by age and cancer exposure. 
Click here to read more.
THE RESEARCH
Click here to read more.
CANCER PREVENTION
Early evidence shows a potential for eRapa™ to prevent the
progression of prostate cancer and Familial Adenomatous Polyposis, a precursor to colon cancer, meeting a significant unmet need in the marketplace.  
Click here to read more.
COGNITIVE DYSFUNCTION
Scientists at the Barshop Institute have demonstrated that orally administered eRapa™ can prevent the development of Alzheimer’s pathologies in mice. 
Click here to read more.
eRAPA NEWS
Over the past decade, Rapamycin has shown promise as a drug
that not only can extend life by delaying the onset of aging-related diseases such as cancer, heart disease, and Alzheimer’s disease, but also postpone the effects of normal aging. 
Click here to read more.
HOME
ABOUT US
OUR TECHNOLOGY
CONTACT US
NEWS
INVESTORS
info@rapamycinholdings.com

210-710-2867
Copyright © 2018 Rapamycin Holdings, Inc. All rights reserved. Click here to view 
Terms of Use
.